The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Biomarkers of response to checkpoint inhibitors in untreated mNSCLC
Natalie Vokes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, compares dual and single agent checkpoint inhibitor therapy in treatment-naïve metastatic non-small cell lung cancer (mNSCLC). Whilst addition of CTLA-4 inhibitors result in long-term immune responses, only certain patients may benefit due to high toxicity. PD-L1 additionally has shown not to be a strong indicator for CTLA-4 response, but STK11 and KEAP1 may be linked to CTLA-4 response. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
